Argenica Therapeutics Ltd
ASX:AGN

Watchlist Manager
Argenica Therapeutics Ltd Logo
Argenica Therapeutics Ltd
ASX:AGN
Watchlist
Price: 0.725 AUD 8.21% Market Closed
Market Cap: 92.9m AUD

Intrinsic Value

AGN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one AGN stock under the Base Case scenario is 0.03 AUD. Compared to the current market price of 0.725 AUD, Argenica Therapeutics Ltd is Overvalued by 96%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AGN Intrinsic Value
0.03 AUD
Overvaluation 96%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Argenica Therapeutics Ltd

AGN
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for AGN cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Argenica Therapeutics Ltd
ASX:AGN
AU
Pharmaceuticals
Market Cap
92.9m AUD
IPO
Jun 11, 2021
AU
Pharmaceuticals
Market Cap
92.9m AUD
IPO
Jun 11, 2021
Price
AU$false
EPS
AU$false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about AGN?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Argenica Therapeutics Ltd
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Argenica Therapeutics Ltd

Balance Sheet Decomposition
Argenica Therapeutics Ltd

Current Assets 15.4m
Cash & Short-Term Investments 15.1m
Receivables 262.3k
Other Current Assets 69.6k
Non-Current Assets 1k
Intangibles 1k
Efficiency

Free Cash Flow Analysis
Argenica Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Argenica Therapeutics Ltd

Revenue
413.8k AUD
Operating Expenses
-5.9m AUD
Operating Income
-5.5m AUD
Other Expenses
245k AUD
Net Income
-5.3m AUD
Fundamental Scores

AGN Profitability Score
Profitability Due Diligence

Argenica Therapeutics Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROIC
Exceptional 1-Year Revenue Growth
ROE is Increasing
36/100
Profitability
Score

Argenica Therapeutics Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

AGN Solvency Score
Solvency Due Diligence

Argenica Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Argenica Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AGN Price Targets Summary
Argenica Therapeutics Ltd

There are no price targets for AGN.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Argenica Therapeutics Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for AGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AGN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one AGN stock?

The intrinsic value of one AGN stock under the Base Case scenario is 0.03 AUD.

Is AGN stock undervalued or overvalued?

Compared to the current market price of 0.725 AUD, Argenica Therapeutics Ltd is Overvalued by 96%.

Back to Top